Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies

IvelinRadkov

• Shares of Prothena Corporation (NASDAQ:PRTA) added ~11% in the premarket on Monday after the biotech said its partner Roche (OTCQX:RHHBF) will advance prasinezumab, its investigational therapy for Parkinson’s disease, into Phase 3 development.
• The Swiss drugmaker’s decision to advance the